Equities

CSMED

DK0061668225

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-26 pm EDT			5-day change	1st Jan Change
6.33 ^DKK	-0.31%		+5.39%	+35.18%

May. 23	Transcript : CS Medica A/S, H1 2024 Earnings Call, May 23, 2024
May. 17	CS Medica A/S Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

CS MEDICA A/S Enters New Partnership with Award-Winning OTC Company Holding a Strong Position in the Chronic Pain Segment in Germany

April 30, 2024 at 07:33 am EDT

CS MEDICA A/S Accelerates European Expansion by Launching 10T Innovative Pain Patches in its Main Territory.

CS MEDICA A/S, a MedTech innovator in cannabinoid-infused treatments, has entered a partnership with an undisclosed fast-growing, award-winning German OTC company. This company holds a strong position in the chronic pain segment in German pharmacies and is actively seeking innovative products to expand its own-labeled CBD portfolio. The collaboration will start with the MDR-compliant medical device; the Pain Patch, with the first 10.000 (10T) units ordered--more products are likely to be added later. The Pain Patch's launch is scheduled for Q3-2024. Detailed information will be published on launch day.

This partnership underscores CS MEDICA's strategic focus on Europe with Germany, a key market due to its size and maturity for CBD-infused products, mirroring the growing interest in the UK, Italy, and other EU markets. With this launch, CS MEDICA extends its commitment to providing natural, science-based, and effective health solutions. Additionally, the expedited process from initial contact to a paid invoice in just nine days is a testament to the company's market responsiveness and improved efficiency.

For further insights into CS MEDICA and the innovative Pain Patch, please visit https://www.cs-medica.com/ and https://www.cannasen.com/product/pain-patch

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: "CSMED"). For more information, visit cs-medica.com and LinkedIn.

https://news.cision.com/cs-medica-a-s/r/cs-medica-a-s-enters-new-partnership-with-award-winning-otc-company-holding-a-strong-position-in-the,c3970398

Latest news about CS MEDICA A/S

Transcript : CS Medica A/S, H1 2024 Earnings Call, May 23, 2024	May. 23
CS Medica A/S Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 17	CI
CS Medica A/S Enters New Partnership with OTC Company Holding A Strong Position in the Chronic Pain Segment in Germany	Apr. 30	CI
CS Medica A/S Advances Global Reach with 180° Drug Store Alliance, Powered by Pull Market Strategy	Apr. 22	CI
Transcript : CS Medica A/S, Q4 2023 Earnings Call, Apr 12, 2024	Apr. 12
CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia	Apr. 04	CI
Transcript : CS Medica A/S, 2023 Earnings Call, Feb 21, 2024	Feb. 21
CS MEDICA A/S Partners with New Distributor to Launch CANNASEN into Jordan	Feb. 20	CI
CS Medica Obtains Danish Patent for Wound Healing Gel	Feb. 02	MT
CS Medica Set to Launch Pain Patch, Cosmetic Products in Australia	Jan. 26	MT
CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market	Dec. 27	CI
Transcript : CS Medica A/S, Q4 2023 Earnings Call, Dec 05, 2023	Dec. 05
CS Medica A/S Announces Financial Year Change	Nov. 22	CI
CS Medica A/S Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 22	CI
CS Medica A/S Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 22	CI
CS Medica's Nasal Protect Gel Secures Second Patent in Denmark	23-10-31	MT
Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products	23-10-12	CI
Danske Bank Extends DKK 1.2 Million Credit Line to CS MEDICA	23-10-10	CI
CS Medica A/S Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-09-13	CI
CS Medica Secures Denmark Patent for Nasal Spray	23-08-30	MT
Transcript : CS Medica A/S, Q3 2023 Earnings Call, Aug 08, 2023	23-08-08
CS MEDICA A/S Announces Establishment of CANNORDIC India Pvt. Ltd. to Expand Presence in India	23-07-14	CI
CS Medica A/S Signs New Own-Label Agreement on Pain Patch	23-06-21	CI
CS Medica Signs Deal for Future Compliance for CE-marked Medical Devices with CBD in EU	23-06-15	MT
CS MEDICA A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body	23-06-15	CI

Chart CS MEDICA A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar